Ocular Surface Disease as Extraesophageal Gastroesophageal Reflux Disease Manifestation: A Specific Therapeutic Strategy

Author:

Di Zazzo Antonio1,Micera Alessandra2ORCID,Surico Pier Luigi1ORCID,Balzamino Bijorn Omar2,Luccarelli Vitaliana3,Antonini Marco1,Coassin Marco1,Bonini Stefano1

Affiliation:

1. Ophthalmology Complex Operative Unit, University Campus Bio-Medico, Rome, Italy;

2. Research and Development Laboratory for Biochemical, Molecular and Cellular Applications in Ophthalmological Sciences, Research Laboratories in Ophthalmology, IRCCS—Fondazione Bietti, Rome, Italy; and

3. Otorhinolaryngology (ENT) Complex Operative Unit, University Campus Bio-Medico, Rome, Italy.

Abstract

Purpose:Gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) are common gastrointestinal disorders with extraesophageal manifestations (EGERD). Studies showed a correlation between GERD/LPR and ocular discomfort. Our aim was to report the prevalence of ocular involvement in patients with GERD/LPR, describe clinical and biomolecular manifestations, and provide a treatment strategy for this novel EGERD comorbidity.Methods:Fifty-three patients with LPR and 25 healthy controls were enrolled in this masked randomized controlled study. Fifteen naive patients with LPR were treated with magnesium alginate eye drops and oral therapy (magnesium alginate and simethicone tablets) with a 1-month follow-up. Clinical ocular surface evaluation, Ocular Surface Disease Index questionnaire, tear sampling, and conjunctival imprints were performed. Tear pepsin levels were quantified by ELISA. Imprints were processed for human leukocyte antigen-DR isotype (HLA-DR) immunodetection and for HLA-DR, IL8, mucin 5AC (MUC5AC), nicotine adenine dinucleotide phosphate (NADPH), vasoactive intestinal peptide (VIP), and neuropeptide Y (NPY) transcript expression (PCR).Results:Patients with LPR had significantly increased Ocular Surface Disease Index (P< 0.05), reduced T-BUT (P< 0.05), and higher meibomian gland dysfunction (P< 0.001) compared with controls. After treatment, tear break-up time (T-BUT) and meibomian gland dysfunction scores improved to normal values. Pepsin concentration increased in patients with EGERD (P= 0.01) and decreased with topical treatment (P= 0.0025), significantly. HLA-DR, IL8, and NADPH transcripts were significantly increased in the untreated versus controls and comparable significant values were obtained after treatment (P< 0.05). MUC5AC expression significantly increased with treatment (P= 0.005). VIP transcripts were significantly higher in EGERD than in controls and decreased with the topical treatment (P< 0.05). No significant changes were observed in NPY.Conclusions:We report an increase in prevalence of ocular discomfort in patients with GERD/LPR. The observations of VIP and NPY transcripts demonstrate the potential neurogenic nature of the inflammatory state. Restoration of the ocular surface parameters suggests the potential usefulness of topical alginate therapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology

Reference21 articles.

1. Presentation and epidemiology of gastroesophageal reflux disease;Richter;Gastroenterology,2018

2. Laryngeal disorders in patients with gastroesophageal reflux disease;Farrokhi;Minerva Gastroenterol Dietol,2007

3. Laryngeal manifestations of gastroesophageal reflux disease;Vaezi;Curr Gastroenterol Rep,2008

4. Gastroesophageal reflux/laryngopharyngeal reflux disease: a critical analysis of the literature;Kotby;Eur Arch Otorhinolaryngol,2010

5. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery;Koufman;Otolaryngol Head Neck Surg,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3